A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
This summary covers the latest health-related news, including FDA's approval of Spravato as a standalone depression treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback